ProKidney Corp - Class A — Balance Sheet (NASDAQ:PROK) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 251.2 M518 M420.55 M441.07 M335.57 M Total liabilities 9.58 M13.06 M29.22 M39.44 M34.78 M Total equity -8.39 M-1.1 B-1.1 B-994.95 M-1.01 B Total liabilities & shareholders' equities 251.2 M518 M420.55 M441.07 M335.57 M Total debt ————— Net debt —————

News

Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK)

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:PROK) 2026-01-14

H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target

This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Compass Minerals Intl (NYSE:CMP), MYR Group (NASDAQ:MYRG)

ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy

ProKidney Corp. (PROK) Presents at Morgan Stanley 23rd Annual

ProKidney at Morgan Stanley Conference: Strategic Insights on CKD Therapy

ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript

ProKidney at Citi’s Biopharma Back to School Conference: CKD Therapy Progress